Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid Post published:November 18, 2024 Post category:Analysis/News
Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences Phase 3; CaaMTech Claims It’s Solved Functional Unblinding Post published:November 15, 2024 Post category:Psychedelic Bulletin/Pα+
Tripping Over Trump: Will the New Administration Embrace Psychedelic Exceptionalism or ‘Just Say No’? Post published:November 14, 2024 Post category:Analysis/News
Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and Decriminalisation Post published:November 6, 2024 Post category:Analysis/News
Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates Post published:November 4, 2024 Post category:Analysis/News
Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future of Psychedelic Research and Regulation Under Trump or Harris Post published:November 4, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control; A Look at the Latest Oregon Psilocybin Services Complaints Post published:November 1, 2024 Post category:Psychedelic Bulletin/Pα+
OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question 4 Post published:October 31, 2024 Post category:Opinions
Backed by $15m in NIDA Funding, NYU and B.More Team Up to Trial Psilocybin for Opioid Use Disorder Post published:October 31, 2024 Post category:Analysis/News/Pα+